Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615756 | 0.80 | HTT (0.62) | HTTALDH1A1NPC1KDM4EKMT2A | |
| SCHEMBL4322956 | 0.80 | HTT (0.62) | HTTALDH1A1NPC1KDM4EKMT2A | |
| SCHEMBL1617024 | 0.80 | HTT (0.62) | HTTALDH1A1NPC1KDM4EKMT2A | |
| SCHEMBL10157137 | 0.80 | MEN1 (0.41) | HTTALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL8300135 | 0.77 | HTT (0.58) | HTTALDH1A1NPC1KDM4EKMT2A | |
| SCHEMBL23000164 | 0.77 | HTT (0.62) | HTTALDH1A1NPC1KDM4EKMT2A | |
| SCHEMBL4451432 | 0.77 | HTT (0.62) | HTTALDH1A1NPC1KDM4EKMT2A | |
| SCHEMBL6174378 | 0.77 | HTT (0.62) | HTTALDH1A1NPC1KDM4EKMT2A | |
| SCHEMBL4322952 | 0.75 | HTT (0.60) | HTTALDH1A1NPC1KDM4EKMT2A | |
| SCHEMBL19652074 | 0.75 | HTT (0.60) | HTTALDH1A1NPC1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895551-B2 | Acrylamide compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | TRPA1, TRPV1, CACNA1B | HTT 382/4885ALDH1A1 809/4885NPC1 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.